Merck extends 2 million euros support to India for coronavirus relief
Science and technology firm Merck on Tuesday announced a support of 2 million euros (Rs 17.85 crore) for India to help the country fight against Covid-1901-06-2021
01-06-2021
Ivermectin for Covid-19: Not enough evidence, warn WHO and doctors
A study by Merck, a manufacturer of Ivermectin, found that there is no scientific basis for a potential therapeutic effect against Covid-19 from pre-clinical studies11-05-2021
Some CEOs suggest dropping degree requirements in hiring
Merck CEO and former IBM CEO say removing conventional requirements for jobs can diversify talent pools06-05-2021
Procter & Gamble Health Ltd - 500126 - Unaudited Financial Results For The Quarter Ended March 31, 2021
We are pleased to inform you that at the meeting of the Board of Directors of the Company held today, the Unaudited Financial Results for the quarter ended March 31, 2021 were approved. We are enclosing herewith the following: a. Unaudited Financial Results for the quarter ended March 31, 2021; b. Press Release; and c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended March 31, 2021 furnished by Statutory Auditors of the Company. Kindly take the same on record and oblige.06-05-2021
Procter & Gamble Health Ltd - 500126 - Unaudited Financial Results For The Quarter Ended March 31, 2021
We are pleased to inform you that at the meeting of the Board of Directors of the Company held today, the Unaudited Financial Results for the quarter ended March 31, 2021 were approved. We are enclosing herewith the following: a. Unaudited Financial Results for the quarter ended March 31, 2021; b. Press Release; and c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended March 31, 2021 furnished by Statutory Auditors of the Company. Kindly take the same on record and oblige.06-05-2021
Procter & Gamble Health Ltd - 500126 - Unaudited Financial Results For The Quarter Ended March 31, 2021
We are pleased to inform you that at the meeting of the Board of Directors of the Company held today, the Unaudited Financial Results for the quarter ended March 31, 2021 were approved. We are enclosing herewith the following: a. Unaudited Financial Results for the quarter ended March 31, 2021; b. Press Release; and c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended March 31, 2021 furnished by Statutory Auditors of the Company. Kindly take the same on record and oblige.06-05-2021
Procter & Gamble Health Ltd - 500126 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We have been informed by the shareholder, about the loss /misplacement of the share certificate as detailed in the attachment.30-04-2021
Procter & Gamble Health Ltd - 500126 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India30-04-2021
Hetero-Merck alliance seeks emergency use nod for anti-COVID drug Molnupiravir in India
Under this licensing deal, Hetero will be allowed to sell Molnupiravir in India and in other low-and middle-income countries (LMICs), following the approvals for emergency use authorisation by local regulatory agencies27-04-2021
Procter & Gamble Health Ltd - 500126 - Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended March 31, 2021
Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/05/2021 ,inter alia, to consider and approve the unaudited financial results for the quarter ended March 31, 2021.27-04-2021